Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Protocol for the Use of Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

NCT00906516 is registered in ClinicalTrials.gov with Bradmer Pharmaceuticals Inc. as lead sponsor.

NCT NCT00906516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00906516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Protocol for the Use of Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme
Lead sponsor
Bradmer Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2009
Completion date
December 31, 2010
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumors